The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial
Background: Given the potential anti-ischemic effects of allopurinol, we aimed to assess whether allopurinol administration may reduce myocardial injury following non-ST elevation myocardial infarction (NSTEMI). Methods: A randomized clinical trial (RCT) was conducted on 100 individuals with NSTEMI....
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Tabriz University of Medical Sciences
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1303c2d95f864733a97c57e1b2573ddc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1303c2d95f864733a97c57e1b2573ddc |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1303c2d95f864733a97c57e1b2573ddc2021-11-29T05:53:42ZThe Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial2383-288610.34172/PS.2021.14https://doaj.org/article/1303c2d95f864733a97c57e1b2573ddc2021-12-01T00:00:00Zhttps://ps.tbzmed.ac.ir/PDF/ps-27-560.pdfhttps://doaj.org/toc/2383-2886Background: Given the potential anti-ischemic effects of allopurinol, we aimed to assess whether allopurinol administration may reduce myocardial injury following non-ST elevation myocardial infarction (NSTEMI). Methods: A randomized clinical trial (RCT) was conducted on 100 individuals with NSTEMI.The intervention group (n=50) received 600 mg oral allopurinol at the time of diagnosis ofNSTEMI, followed by 300 mg every day for two next days and the standard treatment of NSTEMI, while the control group (n=50) received only the standard treatment. Serum concentrations of cardiac troponin I (cTnI) were measured at baseline, and 8, 16, 24, and 32 hours after the treatment. Results: The baseline demographic and clinical data of the patients were not statistically different between the intervention and control groups (all P > 0.05). The comparing estimated marginal mean ± standard error for cardiac troponin I (cTnI) levels revealed no significant difference between the study groups (2.93 ± 0.27, 2.25 ± 0.27; P=0.082). The linear mixed model results showed that the interaction of time and group was not statistically different (P=0.751). Moreover, there was a decreasing trend over time for cTnI in both groups (P=0.039). Conclusion: The present pilot RCT did not support the potential cardio-protective benefits of allopurinol administration on decreasing myocardial injury following NSTEMI.Sajad KhialiParvin SarbakhshSina MashayekhiElham MohamadrezapourSamaneh DoustiTaher Entezari-MalekiTabriz University of Medical Sciencesarticleallopurinolnstemimyocardial injuryinflammationctniPharmacy and materia medicaRS1-441ENPharmaceutical Sciences, Vol 27, Iss 4, Pp 560-567 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
allopurinol nstemi myocardial injury inflammation ctni Pharmacy and materia medica RS1-441 |
| spellingShingle |
allopurinol nstemi myocardial injury inflammation ctni Pharmacy and materia medica RS1-441 Sajad Khiali Parvin Sarbakhsh Sina Mashayekhi Elham Mohamadrezapour Samaneh Dousti Taher Entezari-Maleki The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| description |
Background: Given the potential anti-ischemic effects of allopurinol, we aimed to assess whether allopurinol administration may reduce myocardial injury following non-ST elevation myocardial infarction (NSTEMI). Methods: A randomized clinical trial (RCT) was conducted on 100 individuals with NSTEMI.The intervention group (n=50) received 600 mg oral allopurinol at the time of diagnosis ofNSTEMI, followed by 300 mg every day for two next days and the standard treatment of NSTEMI, while the control group (n=50) received only the standard treatment. Serum concentrations of cardiac troponin I (cTnI) were measured at baseline, and 8, 16, 24, and 32 hours after the treatment. Results: The baseline demographic and clinical data of the patients were not statistically different between the intervention and control groups (all P > 0.05). The comparing estimated marginal mean ± standard error for cardiac troponin I (cTnI) levels revealed no significant difference between the study groups (2.93 ± 0.27, 2.25 ± 0.27; P=0.082). The linear mixed model results showed that the interaction of time and group was not statistically different (P=0.751). Moreover, there was a decreasing trend over time for cTnI in both groups (P=0.039). Conclusion: The present pilot RCT did not support the potential cardio-protective benefits of allopurinol administration on decreasing myocardial injury following NSTEMI. |
| format |
article |
| author |
Sajad Khiali Parvin Sarbakhsh Sina Mashayekhi Elham Mohamadrezapour Samaneh Dousti Taher Entezari-Maleki |
| author_facet |
Sajad Khiali Parvin Sarbakhsh Sina Mashayekhi Elham Mohamadrezapour Samaneh Dousti Taher Entezari-Maleki |
| author_sort |
Sajad Khiali |
| title |
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| title_short |
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| title_full |
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| title_fullStr |
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| title_full_unstemmed |
The Effects of Allopurinol on Levels of Cardiac Troponin Following Non-ST Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial |
| title_sort |
effects of allopurinol on levels of cardiac troponin following non-st elevation myocardial infarction: a pilot randomized clinical trial |
| publisher |
Tabriz University of Medical Sciences |
| publishDate |
2021 |
| url |
https://doaj.org/article/1303c2d95f864733a97c57e1b2573ddc |
| work_keys_str_mv |
AT sajadkhiali theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT parvinsarbakhsh theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT sinamashayekhi theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT elhammohamadrezapour theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT samanehdousti theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT taherentezarimaleki theeffectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT sajadkhiali effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT parvinsarbakhsh effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT sinamashayekhi effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT elhammohamadrezapour effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT samanehdousti effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial AT taherentezarimaleki effectsofallopurinolonlevelsofcardiactroponinfollowingnonstelevationmyocardialinfarctionapilotrandomizedclinicaltrial |
| _version_ |
1718407569877237760 |